Purdue Pharma

About: Purdue Pharma is a company organization based out in Pickering, Ontario, Canada. It is known for research contribution in the topics: Buprenorphine & Chronic pain. The organization has 622 authors who have published 691 publications receiving 31545 citations. The organization is also known as: Purdue Pharmaceuticals L.P..

A tale of 2 ADFs-with 2 different abuse-deterrent formulations.

Abstract: Letter To Editor: The article by Cicero, Ellis, and Kasper stated that both OxyContin and Opana ER use the same technology to impart abuse-deterrent properties to the products. The authors relied on two references for this information. Unfortunately, the information with those references was inaccurate. Opana ER does, in fact, use INTAC, a hot-melt extrusion, high molecular weight polyethylene-oxide technology that is patentprotected by Grünenthal GmbH. The newer formulation of OxyContin introduced in August 2010, however, does not use INTAC. Although its formulation uses high molecular weight polyethylene-oxide, the final dosage form is convection cured, which is a distinct process from the hot-melt extrusion process used to create INTAC. The technologies themselves could contribute to the differences in postmarketing findings that Cicero et al, point out in their article.

Systems for treating an opioid-induced adverse pharmacodynamic response

Abstract: Disclosed in certain embodiments is a method of treating or preventing an opioid-induced adverse pharmacodynamic response comprising administering to a patient in need thereof an effective amount of buprenorphine.

Methods of manufacturing oral formulations

Abstract: A solid oral controlled-release dosage form of hydrocodone is disclosed, the dosage form comprising an analgesically effective amount of hydrocodone or a pharmaceutically acceptable salt thereof, and controlled release material.

Method of treatment and dosage forms thereof

Abstract: The invention provides an oral dosage form comprising (i) an amount of oxycodone and (ii) an amount of buprenorphine, wherein the weight ratio of the amount of buprenorphine to the amount of oxycodone is greater than 1:40 calculated with the amount of buprenorphine in the dosage form expressed as the equimolar amount of buprenorphine base (Mw = 467.64 g/mol) in mg, and the amount of oxycodone in the dosage form expressed as the equimolar amount of oxycodone hydrochloride (Mw = 351.82 g/mol) in mg. The invention also provides combinations of an opioid agonist and buprenorphine for use to treat pain, wherein the combination achieves a reduction of adverse pharmacodynamic responses (such as, respiratory depression), compared with a corresponding stand-alone opioid therapy. The invention also includes methods of treatment and dosage forms thereof comprising such combinations.